Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 36.24 Million CNY | -59.41% |
| 2022 | 89.29 Million CNY | 104.3% |
| 2021 | 43.7 Million CNY | -14.37% |
| 2020 | 51.04 Million CNY | -36.39% |
| 2019 | 80.23 Million CNY | 15.57% |
| 2018 | 69.43 Million CNY | -5.61% |
| 2017 | 73.55 Million CNY | -22.21% |
| 2016 | 94.55 Million CNY | 66.96% |
| 2015 | 56.63 Million CNY | -20.74% |
| 2014 | 71.45 Million CNY | 39.43% |
| 2013 | 51.25 Million CNY | 8.6% |
| 2012 | 47.19 Million CNY | 7.71% |
| 2011 | 43.81 Million CNY | 388.59% |
| 2010 | -15.18 Million CNY | 41.18% |
| 2009 | -25.81 Million CNY | -3.09% |
| 2008 | -25.04 Million CNY | -32.83% |
| 2007 | -18.85 Million CNY | 17.75% |
| 2006 | -22.92 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 25.96 Million CNY | 219.73% |
| 2024 Q2 | 24.79 Million CNY | -4.52% |
| 2023 Q2 | 15.8 Million CNY | -33.89% |
| 2023 FY | 36.24 Million CNY | -59.41% |
| 2023 Q3 | 18.21 Million CNY | 15.23% |
| 2023 Q1 | 23.91 Million CNY | -36.03% |
| 2023 Q4 | -21.68 Million CNY | -219.07% |
| 2022 FY | 89.29 Million CNY | 104.3% |
| 2022 Q4 | 37.38 Million CNY | 59.31% |
| 2022 Q1 | 16.49 Million CNY | 133.2% |
| 2022 Q2 | 11.95 Million CNY | -27.53% |
| 2022 Q3 | 23.46 Million CNY | 96.35% |
| 2021 Q1 | 22.32 Million CNY | 59.94% |
| 2021 Q4 | 7.07 Million CNY | -28.3% |
| 2021 Q3 | 9.86 Million CNY | 121.81% |
| 2021 FY | 43.7 Million CNY | -14.37% |
| 2021 Q2 | 4.44 Million CNY | -80.08% |
| 2020 Q4 | 13.95 Million CNY | -2.19% |
| 2020 FY | 51.04 Million CNY | -36.39% |
| 2020 Q1 | 13.12 Million CNY | -49.58% |
| 2020 Q2 | 9.69 Million CNY | -26.15% |
| 2020 Q3 | 14.26 Million CNY | 47.22% |
| 2019 Q3 | 26.04 Million CNY | 146.86% |
| 2019 Q2 | 10.55 Million CNY | -40.1% |
| 2019 FY | 80.23 Million CNY | 15.57% |
| 2019 Q1 | 17.61 Million CNY | -34.46% |
| 2019 Q4 | 26.03 Million CNY | -0.05% |
| 2018 Q1 | 18.95 Million CNY | -5.3% |
| 2018 FY | 69.43 Million CNY | -5.61% |
| 2018 Q4 | 26.87 Million CNY | 37.19% |
| 2018 Q3 | 19.58 Million CNY | 387.36% |
| 2018 Q2 | 4.01 Million CNY | -78.79% |
| 2017 FY | 73.55 Million CNY | -22.21% |
| 2017 Q3 | 18.18 Million CNY | 8.92% |
| 2017 Q2 | 16.69 Million CNY | -10.49% |
| 2017 Q1 | 18.65 Million CNY | -55.17% |
| 2017 Q4 | 20.01 Million CNY | 10.03% |
| 2016 Q1 | 16.37 Million CNY | 17.45% |
| 2016 Q2 | 17.5 Million CNY | 6.92% |
| 2016 Q3 | 19.06 Million CNY | 8.95% |
| 2016 FY | 94.55 Million CNY | 66.96% |
| 2016 Q4 | 41.61 Million CNY | 118.23% |
| 2015 Q1 | 21.03 Million CNY | 162.0% |
| 2015 Q2 | 10.66 Million CNY | -49.32% |
| 2015 FY | 56.63 Million CNY | -20.74% |
| 2015 Q4 | 13.93 Million CNY | 26.7% |
| 2015 Q3 | 11 Million CNY | 3.2% |
| 2014 FY | 71.45 Million CNY | 39.43% |
| 2014 Q2 | 22.94 Million CNY | -1.85% |
| 2014 Q4 | 8.02 Million CNY | -53.07% |
| 2014 Q3 | 17.1 Million CNY | -25.44% |
| 2014 Q1 | 23.37 Million CNY | 5666.19% |
| 2013 FY | 51.25 Million CNY | 8.6% |
| 2013 Q4 | -420 Thousand CNY | -103.59% |
| 2013 Q1 | 23.98 Million CNY | 420.0% |
| 2013 Q3 | 11.7 Million CNY | -26.77% |
| 2013 Q2 | 15.98 Million CNY | -33.36% |
| 2012 Q2 | 26.06 Million CNY | 30.33% |
| 2012 Q4 | -7.49 Million CNY | -186.86% |
| 2012 Q3 | 8.62 Million CNY | -66.89% |
| 2012 Q1 | 19.99 Million CNY | 221.27% |
| 2012 FY | 47.19 Million CNY | 7.71% |
| 2011 Q3 | 28.91 Million CNY | 90.68% |
| 2011 FY | 43.81 Million CNY | 388.59% |
| 2011 Q1 | 12.78 Million CNY | 220.93% |
| 2011 Q2 | 15.16 Million CNY | 18.6% |
| 2011 Q4 | -16.49 Million CNY | -157.03% |
| 2010 Q1 | -5.19 Million CNY | 38.77% |
| 2010 FY | -15.18 Million CNY | 41.18% |
| 2010 Q4 | -10.57 Million CNY | -285.41% |
| 2010 Q3 | 5.7 Million CNY | 211.43% |
| 2010 Q2 | -5.11 Million CNY | 1.44% |
| 2009 Q2 | -6.04 Million CNY | 0.0% |
| 2009 Q3 | -8.72 Million CNY | -44.16% |
| 2009 FY | -25.81 Million CNY | -3.09% |
| 2009 Q4 | -8.48 Million CNY | 2.74% |
| 2008 FY | -25.04 Million CNY | -32.83% |
| 2007 FY | -18.85 Million CNY | 17.75% |
| 2006 FY | -22.92 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 74.654% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 98.639% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 544.107% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 11.331% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 169.463% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -0.572% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 88.32% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 154.883% |
| SSY Group Limited | 1.63 Billion HKD | 97.788% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 79.192% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 89.119% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 99.702% |